Motilal Oswal Sees 17% Upside In Global Health, Says Expansion To Drive Long-Term Growth — Check Target Price

NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

We continue to value Medanta at 30 times 12 months EV/Ebitda multiple, arriving at a target price of Rs 1,480. Backed by strong operational momentum over the next three-five years and a well-defined expansion pipeline that strengthens revenue visibility beyond FY28.

We reiterate our Buy rating on the stock.

We expect 21%/6% CAGR in Ebitda for developing (ex-Noida) and matured hospitals. Overall, we expect a healthy scale-up of Ebitda (16% CAGR including Noida operations) over FY26-28 to Rs 14 billion.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.